IQVIA HoldingsFRA:QTS +1.58%88 Interest Coverage is 2.94 as of Mar. 2026, which is 5% below its 10-year median of 3.11. GuruFocus rates FRA:QTS with a GF Score™ of 88/100 and a GF Value™ of €217.39 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, IQVIA Holdings ranks worse than 81.91% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. IQVIA Holdings's
Operating Income
for the
three
months ended in Mar. 2026 was €489 Mil. IQVIA Holdings's Interest Expense for the
three
months ended in Mar. 2026 was €-166 Mil.
IQVIA Holdings's interest coverage for the quarter that ended in Mar. 2026 was 2.94.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for IQVIA Holdings's Interest Coverage or its related term are showing as below:
FRA:QTS'
s Interest Coverage Range Over the Past 10 Years
Min: 1.88 Med: 3.11 Max: 5.29
Current: 3.08
FRA:QTS's Interest Coverage is ranked worse than 81.91% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs FRA:QTS: 3.08
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
IQVIA Holdings Interest Coverage Related Terms
IQVIA Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:QTS vs NTRA, ILMN, MTD: Interest Coverage Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (FRA:QTS) has a Interest Coverage of 2.94 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IQVIA Holdings and its competitors. This is near median its historical median of 3.11. Over the past decade, IQVIA Holdings' Interest Coverage has ranged from 1.88 to 5.29. According to the industry distribution chart, IQVIA Holdings ranks #77 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 81.9%.
Is IQVIA Holdings' Interest Coverage too high?
IQVIA Holdings' current Interest Coverage of 2.94 is near median its 10-year median of 3.11. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 5.29. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. IQVIA Holdings' value of 2.94 is 67.9% below this industry median. Based on the distribution chart, IQVIA Holdings ranks #77 out of 94 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Interest Coverage compare to NTRA and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #77 out of 94 companies for Interest Coverage. This places IQVIA Holdings in the lower half of its industry. The industry median Interest Coverage is 9.16. IQVIA Holdings' value of 2.94 is 67.9% below this benchmark. Historically, IQVIA Holdings' own Interest Coverage has ranged from 1.88 to 5.29 over the past decade. While the company's 10-year median is 3.11 vs. the industry median of 9.16, IQVIA Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current Interest Coverage of 2.94 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current Interest Coverage is 2.94, which is near median its own 10-year median of 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €217.39, compared to a current price of €166.85 — trading 23.2% below its estimated fair value. The current Interest Coverage is 2.94, which is near median its 10-year median of 3.11 and 67.9% below the Medical Diagnostics & Research industry median of 9.16. IQVIA Holdings' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current Interest Coverage is 2.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of €166.85 is trading 23.2% below its estimated GF Value™ of €217.39.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for FRA:QTS:
Interest Coverage: 2.94 (near median its 10-year median of 3.11)
GF Value™: €217.39 vs. price of €166.85 (23.2% below fair value)
Industry Position: 67.9% below the Medical Diagnostics & Research median (#77 of 94)
No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score
Get the complete analysis for FRA:QTS
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:QTS has been successfully added to your 
